Search Within

Gastrointestinal Oncology Service

  1. "Future Oncology"
Formats
  1. Journal Article (10)
  2. Review (7)
  3. Editorial (3)
Groups
  1. Department of Medicine (20)
  2. Solid Tumor Oncology Division (20)
  3. Center for Pancreatic Cancer Research (3)
  4. Department of Pathology and Laboratory Medicine (2)
  5. Hematologic Malignancies, Division of (2)
  6. Surgery (2)

More Groups

People
  1. Yelena Janjigian (6)
  2. Ghassan Abou-Alfa (4)
  3. James Harding (3)
  4. David Ilson (2)
  5. Eileen O'Reilly (2)
  6. Geoffrey Ku (2)

More People

Years
  1. 2025 (4)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (4)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Future Oncology (20)
Publishers
  1. Future Medicine (20)

Results (20)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A plain language summary of the molecular changes in the tumors of people with BRAF V600E–mutant colorectal cancer in the BEACON study
    Editorial

    Kopetz, S.; Murphy, D. A.; Pu, J.; Ciardiello, F.; Desai, J.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Saffari, H.; Zhang, X.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • The potential benefit of encorafenib plus cetuximab with chemotherapy compared with standard of care in people with BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study: A plain language summary
    Editorial

    Kopetz, S.; Yoshino, T.; Van Cutsem, E.; Eng, C.; Kim, T. W.; Wasan, H. S.; Desai, J.; Ciardiello, F.; Yaeger, R.; Maughan, T. S.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)
    Editorial

    Wainberg, Z. A.; Melisi, D.; Macarulla, T.; Pazo Cid, R.; Chandana, S. R.; De La Fouchardière, C.; Dean, A.; Kiss, I.; Jin Leei, W.; Goetze, T. O.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • MOUNTAINEER-03 phase III study design: First-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer
    Journal Article

    Strickler, J. H.; Bekaii-Saab, T.; Cercek, A.; Heinemann, V.; Nakamura, Y.; Raghav, K.; Siena, S.; Tabernero, J.; Van Cutsem, E.; Yoshino, T.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save
  • A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
    Journal Article

    Harding, J. J.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla, T.; Xie, F.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: A plain language summary
    Review

    Shitara, K.; Shah, M. A.; Lordick, F.; Bang, Y. J.; Ilson, D.; Van Cutsem, E.; Enzinger, P.; Kim, S. S.; Klempner, S. J.; Moran, D.; more...
    Future Oncology (2024)

    Fulltext@MSK | Save
  • Plain language summary of the HIMALAYA study: Tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)
    Review

    Abou-Alfa, G. K.; Lau, G.; Kudo, M.; Chan, S. L.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; more...
    Future Oncology (2023)

    Fulltext@MSK | Save
  • A plain language summary of the CheckMate 649 study: Nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus
    Review

    Janjigian, Y. Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; Liu, T.; more...
    Future Oncology (2023)

    Fulltext@MSK | Save
  • Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    Review

    de Castria, T. B.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
    Review

    Tabernero, J.; Shen, L.; Elimova, E.; Ku, G.; Liu, T.; Shitara, K.; Lin, X.; Boyken, L.; Li, H.; Grim, J.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save